Mass General Brigham Spinout Aevius Launches with $22 Million to Advance AI in Healthcare

0
10
Aevius co-founders (from left to right): Long Phi Le, Rowland Pettit, Ming Yang (Max) Lu, and Faisal Mahmood. Photo credit: Aevius

BOSTON–Aevius, an artificial intelligence company spun out of Mass General Brigham, has launched with $22 million in funding led by Insight Partners to develop technology that transforms fragmented medical records into actionable information for healthcare providers, insurers, and life sciences companies.

The Boston-based startup plans to use the investment to expand its engineering, clinical, and commercial teams, advance its AI models and products, and support commercial deployment.

Aevius is developing AI technology designed to analyze structured and unstructured medical records, including specialized clinical data, to help healthcare organizations better understand patients, predict outcomes, and support clinical research.

The company was founded by Rowland Pettit, M.D., Ph.D., Ming Yang (Max) Lu, Ph.D., Faisal Mahmood, and Long Phi Le, who were part of the founding team behind Modella AI, a medical AI company acquired by AstraZeneca.

The founders are applying their experience in medical artificial intelligence to a broader challenge facing the healthcare industry: making large volumes of patient information accessible and useful for clinical decision-making.

Although healthcare organizations have invested heavily in electronic medical records, much of the information remains scattered across different systems and formats, making it difficult to analyze and apply consistently.

Aevius aims to address that problem by developing AI models capable of interpreting multiple types of medical data and identifying relationships across a patient’s clinical history.

“Our mission is to make medicine computable,” said Rowland Pettit, M.D., Ph.D., Co-Founder and Chief Executive Officer of Aevius. “As a physician-scientist, I’ve worked across many types of clinical data, and there is far more knowledge in those records than we’re able to use today. We’re bringing general medical intelligence to that data, so organizations can build on a deeper understanding for their patients.”

The company’s technology creates what it describes as a continuously updated representation of a patient’s medical condition and history.

By combining information from different sources, the system is designed to provide healthcare organizations with a more comprehensive understanding of a patient’s clinical status and how it changes over time.

Organizations can use these representations to develop multiple applications without repeatedly processing the same medical information.

Potential uses include predicting patient outcomes, identifying individuals with similar medical conditions, analyzing patient populations, and monitoring changes in health status.

“Most AI agents today piece together their picture of a patient from text, one question at a time,” said Ming Yang (Max) Lu, Ph.D., Co-Founder and Chief Technology Officer of Aevius. “We’re building a native representation of each patient’s multimodal, longitudinal history that powers prediction and analysis across an entire population. Researchers, care teams and AI agents can take on new questions without starting over, working from the whole patient rather than fragments of a record.”

The company is targeting three primary markets: healthcare systems, health insurers, and life sciences organizations.

For hospitals and healthcare providers, Aevius aims to support clinical research, anticipate patient needs, and improve decisions related to care delivery and resource allocation.

For health insurers, the technology could help identify patients who may benefit from earlier interventions and more coordinated care.

In the life sciences industry, Aevius plans to support research into disease progression, treatment outcomes, and the identification of potential biomarkers.

The technology could also help pharmaceutical and biotechnology companies identify suitable participants for clinical trials and better understand how diseases respond to different treatments.

“The value of medical AI will be measured by how well it promotes accuracy,” said Eric Topol, M.D., Chair of Aevius’s Scientific Advisory Board. “Aevius is pursuing that goal with models grounded in the breadth and complexity of patients’ medical histories.”

Aevius emerged from research conducted at Mass General Brigham, one of the country’s major academic healthcare systems.

The organization said the spinout reflects its efforts to bring healthcare innovations developed within its research institutions to a broader commercial market.

“Mass General Brigham develops AI with the ambition to improve healthcare far beyond our own hospitals,” said Chris Coburn, Chief Innovation Officer at Mass General Brigham. “Aevius was spun out of MGB to bring together research developed here and a team with experience taking medical AI to market. We expect that organizations throughout care delivery and life sciences will soon benefit from this powerful technology.”

Insight Partners, which led the $22 million financing, said the investment reflects growing demand for technologies capable of extracting useful information from complex clinical datasets.

“As with other industries, AI in healthcare is only as valuable as the data that drives it, and clinical data is among the hardest to unlock,” said Dylan Morris, Managing Director at Insight Partners. “Aevius is a rare combination of talent and technology. We are thrilled to back these inspiring founders and their vision to make medicine computable, deliver clinical intelligence to the enterprise, and ultimately improve outcomes for patients.”

The funding will allow Aevius to continue developing its technology while expanding its operations and pursuing commercial partnerships with healthcare and life sciences organizations.

The company has not disclosed specific customer agreements or a timeline for broader commercial deployment.

Leave A Reply

Please enter your comment!
Please enter your name here